D
David R. Gandara
Researcher at University of California, Davis
Publications - 725
Citations - 45633
David R. Gandara is an academic researcher from University of California, Davis. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 84, co-authored 685 publications receiving 40321 citations. Previous affiliations of David R. Gandara include National Institutes of Health & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Association between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the Ph III study OAK
Niels Reinmuth,Kostas N. Syrigos,Julien Mazieres,Diego Cortinovis,R Dziadziuszko,David R. Gandara,P Conkling,J. Goldschmidt,C.A. Thomas,Rodolfo Bordoni,Michael P. Kosty,Fadi Braiteh,Sylvia Hu,Marcus Ballinger,Hina Patel,M. Gandhi,Louis Fehrenbacher +16 more
Journal ArticleDOI
Phase I study of PS-341 (bortezomib) with 5-fluorouracil/leucovorin (5-FU/LV) in advanced solid tumors: A California Cancer Consortium study
Syma Iqbal,Sarah Cole,D. Y. Yang,Primo N. Lara,Paul H. Gumerlock,Stephen Shibata,Timothy W. Synold,James H. Doroshow,David R. Gandara,H. J. Lenz +9 more
TL;DR: PS-341, when given twice weekly with once weekly 5-FU 500 mg/m2/LV 20 mg/ m2 for 4 weeks, followed by 2 weeks rest is a safe regimen for Phase II testing.
Journal ArticleDOI
Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer
Cheryl Ho,Angela M. Davies,Randeep Sangha,Derick H Lau,Primo N. Lara,Helen K. Chew,Laurel A. Beckett,Philip C. Mack,Jonathan W. Riess,David R. Gandara +9 more
TL;DR: Evaluating the safety and efficacy of combining pemetrexed and nanoparticle albumin bound (nab) paclitaxel with a focus on NSCLC for phase II expansion found this regimen was feasible and well tolerated.
Journal ArticleDOI
Chemotherapy Outcomes by Histologic Subtypes of Non-Small cell Lung Cancer: Analysis of the Southwest Oncology Group Database for Antimicrotubule-Platinum Therapy
Karen Kelly,Kari Chansky,Philip C. Mack,Primo N. Lara,Fred R. Hirsch,Wilbur A. Franklin,Antoinette J. Wozniak,Martin J. Edelman,Stephen K. Williamson,David R. Gandara +9 more
TL;DR: This pooled analysis from 4 SWOG trials using an AMT-platinum regimen did not show a difference in survival outcomes by histologic subtype, and defining molecular-based predictive markers of responsiveness is warranted.
Journal ArticleDOI
Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G.
Taofeek K. Owonikoko,Mary W. Redman,Lauren Averett Byers,Fred R. Hirsch,Philip C. Mack,Lawrence H. Schwartz,Jeffrey D. Bradley,Thomas E. Stinchcombe,Natasha B. Leighl,Tareq Al Baghdadi,Primo N. Lara,Jieling Miao,Karen Kelly,Suresh S. Ramalingam,Roy S. Herbst,Vassiliki A. Papadimitrakopoulou,David R. Gandara +16 more
TL;DR: In this paper, a signal finding study was designed to evaluate the efficacy of talazoparib in advanced stage squamous cell lung cancer harboring homologous recombination repair deficiency.